{'fraction_non_alphanumeric': 0.016611295681063124, 'fraction_numerical': 0.0022148394241417496, 'mean_word_length': 4.947368421052632, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Analysis of drug-resistant multi-loci mutation of P area of HBV genome in 32 patients with chronic hepatitis B].

OBJECTIVE
In order to deeply understand the effects of nucleoside analogues to HBV DNA polymerase area, which initiate a state of drug resistance due to HBV genome mutation.


METHODS
Using PCR product direct sequencing method to test the gene sequence of P area of HBV genome of the patients who taking nucleoside analogues and showing signs of virologic breakthrough.


RESULTS
More resistance mutations can be find in HBV DNA polymerase area, which causing clinically cross drug resistance and multiple resistance.


CONCLUSION
We should choose higher genetic barrier for the initial treatment. And the patients long-term using of nucleoside analogues, should be regularly monitored serum HBV DNA level, in order for early detection of virological breakthrough and timely intervention.